Liposomal Drug Delivery System by Signicent

Liposomal Drug Delivery Systems: Why Nanomedicine Seems Promising?

The objective of the report is to explore the domain of liposomal drug delivery systems. The report will include the technology research, market research and competitive aspect of liposomal drug delivery systems in various industries.


The experts of Signicent did a comprehensive analysis of technologies that will include details of innovations surrounding liposome delivery. Various competitors’ key players and associated technologies are also touched upon.

  • Recent technology & innovation trends
  • Market forces impacting ingredients
  • Innovative applications & types of liposomes
  • Future Direction

Liposomal Drug Delivery Systems

A liposome is a closed, spherical lipid bilayer, which forms an internal cavity capable of carrying aqueous solutions. A lipid bilayer is composed of two sheets of tightly arranged phospholipids. These molecules have a hydrophobic tail and a hydrophilic head region. When two single membranes come together, the hydrophobic tails attract each other, while the heads of both membranes are attracted to the surrounding water.

Advantages

Liposomes increased the efficacy and therapeutic index of the drug (actinomycin-D). Increased stability via encapsulation. Liposomes are non-toxic, flexible, biocompatible, completely biodegradable, and non-immunogenic for systemic and non-systemic administrations. Reduce the toxicity of the encapsulated agent (amphotericin B, Taxol). Help to reduce the exposure of sensitive tissues to toxic drugs. Flexibility to couple with site-specific ligands to achieve active targeting.

Innovations in Drug Delivery Systems

Smart pH-responsive stealth liposome: Synthesis of curcumin-loaded smart ph-responsive stealth liposome as a novel nanocarrier for cancer treatment.

Drug Release Pattern

Liposomes are considered to be very good drug delivery agents. However, they have a flaw in their drug release pattern. The drug molecules encapsulated in liposomes show leakage from liposome structure. Moreover, their rapid interaction with the plasma proteins leads to their elimination from the body.

Smart Drug Delivery

Smart drug delivery systems can be chosen to improve the drug molecules’ performance. In smart drug delivery systems, the drug is released in a specific site due to the structural change in response to the intrinsic (pH, and temperature) or extrinsic (light and magnetic) stimulation, leading to a much more efficient way of delivering the drug.

Smart pH-Responsive Drug Delivery Systems

Generally, the pH of cancer tissues is a little less than the pH of normal tissue. This intrinsic feature of the cancer tissues is used to fabricate the smart pH-responsive drug delivery systems.

  • The drug delivery system releases the drug in response to pH change. The invention hereby is aimed to fabricate a new type of smart pH-responsive stealth liposome for the delivery of curcumin as an anticancer drug.
  • Four different types of liposomes (with/without pH-responsive polymeric coating) were synthesized via the Mozafari method. several tests, such as dynamic light scattering (DLS), Fourier-transform infrared spectroscopy (FTIR), Zeta potential, and field emission scanning electron microscopes (FE-S EM) were performed moreover, the loading and release profile of curcumin were evaluated in two pHs of 7.4 and 6.6.

Results:

FE-SEM results revealed that smart stealth-liposome and liposome had a mean size of about 40 and 50 nm, respectively.

However, drug entrapment revealed that non-coated liposomes had about 74% entrapment efficiency, whereas PEGylated liposomes had about 84% of entrapment efficiency

Furthermore, the drug release pattern of the Nano carriers showed more controllable release in stealth-liposome in comparison to non-coated one

Conclusion

Results showed that pH-responsive stealth liposomes had better cytotoxicity against cancer cells. Hence, it could be concluded that this new type of smart liposome could be considered a good candidate for cancer therapy.


Each year Signicent provides consultancy to hundreds of organizations to help transform their innovations to value.


Microfluidic Devices

Traditional fabrication techniques for microfluidic devices have several disadvantages, such as multistep processing and expensive facilities. Furthermore, several small promising small molecule drugs and genes face stability, solubility & non-specific toxicity issues.

Three-dimensional printing (3DP) revolutionized microfluidic device production, boasting facile and low-cost fabrication. Microfluidic devices with innovative micro-mixing patterns were developed using fused deposition modelling (FDM) and liquid crystal display (LCD) printers. Liposomes were produced using the developed microfluidic devices. The effect of microfluidic parameters, chip manufacturing, material, and channel design on liposomal formulation was evaluated.

Conclusion

The microfluidic method was confirmed to be a simple and fast technique for liposome production. However, scaling up the liposome manufacturing process using microfluidics, one future goal is to compare the quality and properties of microfluidic formulations.

Global Liposomal Drug Delivery Market

The global liposome drug delivery market is expected to reach US $8 billion by 2027 from US $3.6 billion in 2018 at a CAGR of 9%. The opportunities involve new strategies for surface modification of liposomes. Also, institutes are accelerating their R&D activities. The rise in the prevalence of diseases is the growth driver. However, maintaining the physical properties of liposomal formulations is a challenge.

Transformative Startup

DIANT Pharma was founded in the year 2019 with Headquarters in CT, United States. Co-founded by Antonio Costa, Ph.D. and Diane Burgess, Ph.D., the company licensed their core manufacturing technology for the production of drugs formulated into liposomes.

The technology was originally developed with an emphasis on liposomal products but now the modular technologies could be used to create a variety of complex medicines and medicine delivery products such as liposomes, lipid nanoparticles, emulsions and polymeric micelles.

Diant Pharma’s continuous manufacturing process has a myriad of benefits in contrast to the traditional batch manufacturing methods. Moreover, the company brings the highest quality products to the patients with a technology that is robust and reliable over a product’s lifespan.

Partnership for Drug Delivery

MindMed and Nextage Therapeutics have joined hands to optimize the delivery of specific psychedelic drug candidates, using Nextage’s proprietary Brain Targeting Liposome System (BTLS) delivery technology.

MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines and therapies to address addiction and mental illness.

Nextage Therapeutics Ltd. is a global pharmaceutical company bringing the scientific clarity and confidence needed to develop the next generation of cannabinoid-based products.

The association between MindMed and Nextage Therapeutics will help optimize the delivery of drug products based on noribogaine. The BTLS technology allows the targeted delivery of active pharmaceutical ingredients (APIs) through the Blood-Brain Barrier. Using this new innovation, MindMed seeks to capitalize on the opportunity to mitigate the serious side effects that make some orally administered psychedelics poor drug candidates.

Competitive Analysis

Plus Therapeutics Announces Two Significant Milestones Toward cGMP Manufacture of its Lead Investigational Radiotherapeutic.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company has announced two significant milestones as it progresses toward cGMP manufacture of Rhenium-186 Nanoliposome (186RNL).


The Company has entered into a master services agreement (MSA) with IsoTherapeutics Group LLC for its development, manufacturing and supply. This agreement will strengthen the Company’s long-term cGMP supply sustainability strategy.

Central Drugs Standard Control Organization (CDSCO) of India has approved TLC’s New Drug Application (NDA) of Amphotericin B Liposome for injection 50 mg. AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis. This approval from CDSCO allows for immediate import and distribution of the product in India and helps ease the crisis arising out of an unprecedented rise in Covid-19-related mucormycosis cases.


Recent Report